Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 2/20 | 0.52 |
| ▸ | CCND1 | P24385 | 2/20 | 0.52 |
| ▸ | GBA1 | P04062 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 4/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | NEK4 | P51957 | 1/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3713601 | 0.89 | CDK4 (0.49) | CDK4CCND1GBA1MEN1KMT2A | |
| SCHEMBL3962080 | 0.82 | CDK4 (0.58) | CDK4CCND1GBA1MEN1KMT2A | |
| SCHEMBL2240341 | 0.80 | CDK4 (0.50) | CDK4CCND1GBA1MEN1KMT2A | |
| SCHEMBL4769102 | 0.79 | KMT2A (0.55) | CDK4CCND1GBA1MEN1KMT2A | |
| SCHEMBL4776165 | 0.77 | CCKBR (0.52) | CDK4CCND1GBA1MEN1KMT2A | |
| SCHEMBL3715061 | 0.76 | GBA1 (0.55) | CDK4CCND1GBA1MEN1KMT2A | |
| SCHEMBL4775038 | 0.76 | CDK4 (0.47) | CDK4CCND1GBA1MEN1KMT2A | |
| SCHEMBL4766503 | 0.75 | CDK4 (0.47) | CDK4CCND1GBA1MEN1KMT2A | |
| SCHEMBL4773620 | 0.75 | CDK4 (0.47) | CDK4CCND1GBA1MEN1KMT2A | |
| SCHEMBL4766487 | 0.75 | CDK4 (0.47) | CDK4CCND1GBA1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231642-B1 | PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-10-23 | — | — | EP | claimed |
| US-8431578-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-04-30 | — | — | US | claimed |
| US-20100298337-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-25 | — | — | US | claimed |
| EP-2231642-A1 | PYRIMIDINES AS KINASE INHIBITORS | Novartis AG (CH) | 2010-09-29 | — | — | EP | claimed |
| WO-2009087224-A1 | PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | claimed |
| EP-2231642-B1 | PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| EP-2231642-B1 | PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2013-10-23 | — | — | EP | disclosed |
| US-8431578-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-04-30 | — | — | US | disclosed |
| US-8431578-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-04-30 | — | — | US | disclosed |
| US-8431578-B2 | Organic compounds | NOVARTIS AG (CH) | 2013-04-30 | — | — | US | disclosed |
| US-20100298337-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-25 | — | — | US | disclosed |
| US-20100298337-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-25 | — | — | US | disclosed |
| US-20100298337-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-25 | — | — | US | disclosed |
| EP-2231642-A1 | PYRIMIDINES AS KINASE INHIBITORS | Novartis AG (CH) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009087224-A1 | PYRIMIDINES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298337-A1 | Organic Compounds | CYP11B2, TNNT2, CPT1B | CDK4 1274/4885CCND1 658/4885GBA1 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.